Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Rhea-AI Summary
Emergent BioSolutions (NYSE: EBS) announced that Joe Papa, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST. An audio link to the session will be available and kept live for up to 30 days. The company said its presentation slides will be posted on the Investors section of the Emergent website at the time of the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – EBS
In the Jan 7 session, EBS gained 5.70%, reflecting a notable positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | FDA approval update | Positive | -2.6% | FDA cleared Winnipeg facility for raxibacumab drug product manufacturing and testing. |
| Nov 18 | Product milestone | Positive | +0.2% | Marked 10-year NARCAN Nasal Spray approval anniversary and highlighted naloxone access efforts. |
| Nov 12 | Board change | Neutral | -4.5% | Announced retirement of long-serving director Louis W. Sullivan from the board. |
| Oct 29 | Earnings results | Positive | -0.7% | Q3 2025 beat revenue guidance and raised full-year outlook with solid margins. |
| Oct 28 | Survey release | Neutral | -2.3% | Released survey on biological threat concerns and highlighted biodefense capabilities. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and earnings headlines have sometimes been followed by negative price reactions, suggesting a pattern of selling into good news.
Over the last few months, Emergent reported multiple milestones, including U.S. FDA approval for raxibacumab manufacturing at its Winnipeg site on Dec 12, 2025 and strong Q3 2025 financials with revenue of $231.1M and net income of $51.2M. Despite these positives and a celebratory 10-year NARCAN® Nasal Spray approval anniversary, several events saw modest to negative price reactions. The current conference appearance follows a phase of operational consolidation, board changes, and public health–focused communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST.
The audio link for Emergent’s session may be accessed here and will be live for up to 30 days.
The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
